Κλαύδιος Γαληνός
Δωρεάν εγγραφή Αποκτήσετε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr για έναν μήνα
Έλεγχος συγχορήγησης Ελέγξτε την αγωγή σας για αντενδείξεις και αλληλεπιδράσεις μεταξύ των φαρμάκων
Μητρότητα και φάρμακα Ενημερωθείτε για την ασφάλεια χορήγησης ενός φαρμάκου κατά τη διάρκεια της εγκυμοσύνης ή του θηλασμού
Συνδρομές Μάθετε περισσότερα για τα οφέλη και τις επιπλέον παροχές των συνδρομητικών προγραμμάτων
Ενδείξεις και αγωγές Βρείτε θεραπευτικές ενδείξεις και αγωγές για νόσους, συμπτώματα και ιατρικές πράξεις
Γνωρίζατε ότι... Μοιραζόμαστε μαζί σας γεγονότα της πορείας του Galinos.gr από το 2011 μέχρι σήμερα

MANIDIPINE Tablet

Αναφορές

Βιβλιογραφική αναφορά

Για την προβολή της πλήρους καταχώρησης απαιτείται συνδρομή σε ισχύ.
Αποκτήστε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr δωρεάν για έναν μήνα απλά κάνοντας εγγραφή.
Δωρεάν εγγραφή

Περιεχόμενα

Name of the medicinal product

Manidipine 10 mg tablets. Manidipine 20 mg tablets.

Qualitative and quantitative composition

Manidipine dihydrochloride 10 mg Excipients: lactose monohydrate 66.40 mg Manidipine dihydrochloride 20 mg Excipients: lactose monohydrate 132.80 mg For a full list of excipients, see Section 6.1.

Pharmaceutical form

Tablet. The 10 mg tablets are round convex, yellow coloured, with midline score line. The 20 mg tablets are oval convex, yellow coloured, with midline score line. The score line is only to facilitate breaking ...

Therapeutic indications

Mild to moderate essential hypertension.

Posology and method of administration

The recommended starting dose is 10 mg once a day. If, after 2-4 weeks of treatment, the anti-hypertensive effect is insufficient, it is advisable to increase the dosage to the usual maintenance dose of ...

Contraindications

Hypersensitivity to the active substance, manidipine, or to other dihydropyridines or to any of the excipients. Children. Unstable angina or within 4 weeks of a myocardial stroke. Untreated congestive ...

Special warnings and precautions for use

Should be administered with caution in patients with mild hepatic impairment, since the antihypertensive effect may be increased (see section 4.2 Posology and method of administration). A reduction of ...

Interaction with other medicinal products and other forms of interaction

As occurs with other dihydropyridine calcium channel blockers, it is probable that manidipine metabolism is catalysed by the cytochrome P450 3A4. Caution should be exercised when Manidipine RKG is administered ...

Fertility, pregnancy and lactation

Pregnancy No clinical data are available about the use of this medicinal product by pregnant women. Studies with manidipine on laboratory animals do not provide sufficient results on foetal development ...

Effects on ability to drive and use machines

Since dizziness may be experienced due to a reduced blood pressure, patients should be advised to take care while driving and operating machinery.

Undesirable effects

A number of undesirable effects have been observed during treatment with Manidipine RKG and other dihydropyridines, with the following frequencies: Very common ≥1/10, Common ≥1/100 to <1/10, Uncommon ≥1/1,000 ...

Overdose

No case of overdose is known. As occurs with other dihydropyridines, it is expected that an overdose would cause excessive peripheral vasodilatation with severe hypotension and reflex tachycardia. In this ...

Pharmacodynamic properties

Pharmacotherapeutic group: selective calcium channel blockers, with mainly vascular effects ATC code: C08CA11 Manidipine is a dihydropyridine calcium channel blocker with anti-hypertensive activity and ...

Pharmacokinetic properties

After oral administration, maximum plasma concentration is achieved in 2-3.5 hours. Manidipine undergoes first-pass metabolism. Binding to plasma proteins is 99%. The medicinal product is widely distributed ...

Preclinical safety data

The results of repeated dose toxicity studies have shown only toxic signs linked to the exacerbation of the pharmacological effects. The toxicological profile of manidipine on reproduction has not been ...

List of excipients

Lactose monohydrate Maize starch Low-substituted hydroxypropylcellulose Hydroxypropylcellulose Magnesium stearate Riboflavin

Incompatibilities

Not applicable.

Shelf life

24 months.

Special precautions for storage

This medicinal product does not require any special storage conditions.

Nature and contents of container

PVC/PVDC blister sealed with Al/PVDC. 10 and 20 mg: 14, 28, 30, 56, 84, 90, 98, 112 tablets. Not all pack sizes may be marketed

Special precautions for disposal and other handling

Any unused product or waste material should be disposed of in accordance with local requirements.

Πηγαίο έγγραφο

Το πηγαίο έγγραφο για αυτήν την βιβλιογραφική αναφορά είναι διαθέσιμο προς μεταφόρτωση:

Μπορείτε να υποστηρίξετε τον Γαληνό στην αποστολή του να παρέχει δωρεάν έγκυρη πληροφόρηση για κάθε φάρμακο απενεργοποιώντας το Ad Blocker για αυτόν τον ιστότοπο.